Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $63.8 million.

  • Protagonist Therapeutics' Shares Outstanding (Weighted Average) rose 324.5% to $63.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.8 million, marking a year-over-year increase of 324.5%. This contributed to the annual value of $61.6 million for FY2024, which is 846.22% up from last year.
  • Protagonist Therapeutics' Shares Outstanding (Weighted Average) amounted to $63.8 million in Q3 2025, which was up 324.5% from $63.5 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $63.8 million for Q3 2025, and its period low was $44.2 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $56.8 million (2023), whereas its average is $55.0 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 5963.15% in 2021, then surged by 233.49% in 2022.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Shares Outstanding (Weighted Average) stood at $46.3 million in 2021, then rose by 6.01% to $49.1 million in 2022, then rose by 15.59% to $56.8 million in 2023, then grew by 8.46% to $61.6 million in 2024, then increased by 3.58% to $63.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $63.8 million for Q3 2025, versus $63.5 million for Q2 2025 and $63.0 million for Q1 2025.